Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LFCR NASDAQ:PHAT NASDAQ:PROK NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$6.81+1.0%$7.24$4.76▼$8.85$252.52M0.62216,288 shs103,260 shsPHATPhathom Pharmaceuticals$13.61+1.1%$11.97$2.21▼$19.50$954.90M0.431.31 million shs634,908 shsPROKProKidney$3.19+0.9%$2.66$0.46▼$7.13$929.93M1.722.20 million shs1.12 million shsTNGXTango Therapeutics$7.53-13.0%$7.49$1.03▼$9.70$963.51M1.672.14 million shs33.76 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical-0.30%+0.75%-14.47%-8.30%+28.38%PHATPhathom Pharmaceuticals-3.86%+0.07%+14.65%+48.73%-18.87%PROKProKidney-4.24%-0.32%+12.46%-3.07%+70.81%TNGXTango Therapeutics-3.67%-9.03%+16.24%+28.30%+30.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$6.81+1.0%$7.24$4.76▼$8.85$252.52M0.62216,288 shs103,260 shsPHATPhathom Pharmaceuticals$13.61+1.1%$11.97$2.21▼$19.50$954.90M0.431.31 million shs634,908 shsPROKProKidney$3.19+0.9%$2.66$0.46▼$7.13$929.93M1.722.20 million shs1.12 million shsTNGXTango Therapeutics$7.53-13.0%$7.49$1.03▼$9.70$963.51M1.672.14 million shs33.76 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical-0.30%+0.75%-14.47%-8.30%+28.38%PHATPhathom Pharmaceuticals-3.86%+0.07%+14.65%+48.73%-18.87%PROKProKidney-4.24%-0.32%+12.46%-3.07%+70.81%TNGXTango Therapeutics-3.67%-9.03%+16.24%+28.30%+30.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLFCRLifecore Biomedical 2.20Hold$8.0017.47% UpsidePHATPhathom Pharmaceuticals 2.71Moderate Buy$17.5028.58% UpsidePROKProKidney 2.17Hold$6.2595.92% UpsideTNGXTango Therapeutics 2.67Moderate Buy$10.5039.44% UpsideCurrent Analyst Ratings BreakdownLatest LFCR, TNGX, PROK, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025LFCRLifecore BiomedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/8/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PROKProKidneyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LFCRLifecore BiomedicalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/27/2025PHATPhathom PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PROKProKidneyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025TNGXTango TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/18/2025TNGXTango TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$11.008/18/2025PROKProKidneyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLFCRLifecore Biomedical$128.87M1.98N/AN/A$0.04 per share170.25PHATPhathom Pharmaceuticals$55.25M17.47N/AN/A($3.71) per share-3.67PROKProKidney$80K11,734.42N/AN/A($3.41) per share-0.94TNGXTango Therapeutics$42.07M19.91N/AN/A$1.86 per share4.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/28/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%10/30/2025 (Estimated)PROKProKidney-$61.19M-$0.57N/AN/AN/AN/AN/A-17.11%11/11/2025 (Estimated)TNGXTango Therapeutics-$130.30M-$1.33N/AN/AN/A-599.11%-79.72%-49.30%11/5/2025 (Estimated)Latest LFCR, TNGX, PROK, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025PROKProKidney-$0.12N/AN/AN/A$0.04 millionN/A11/5/2025Q3 2025TNGXTango Therapeutics-$0.07N/AN/AN/A$41.35 millionN/A10/30/2025Q3 2025PHATPhathom Pharmaceuticals-$0.30N/AN/AN/A$47.03 millionN/A10/28/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/12/2025Q2 2025PROKProKidney-$0.14-$0.13+$0.01-$0.13N/A$0.22 million8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 million8/5/2025Q2 2025TNGXTango Therapeutics-$0.35-$0.35N/A-$0.35$6.41 million$3.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLFCRLifecore BiomedicalN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLFCRLifecore Biomedical113.762.841.77PHATPhathom PharmaceuticalsN/A2.382.35PROKProKidneyN/A11.4811.48TNGXTango TherapeuticsN/A4.754.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLFCRLifecore Biomedical83.36%PHATPhathom Pharmaceuticals99.01%PROKProKidney51.59%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipLFCRLifecore Biomedical31.98%PHATPhathom Pharmaceuticals23.00%PROKProKidney41.49%TNGXTango Therapeutics7.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLFCRLifecore Biomedical69037.47 million25.48 millionOptionablePHATPhathom Pharmaceuticals11070.94 million54.63 millionOptionablePROKProKidney3294.28 million172.18 millionOptionableTNGXTango Therapeutics90111.26 million102.92 millionOptionableLFCR, TNGX, PROK, and PHAT HeadlinesRecent News About These CompaniesTango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers TranscriptOctober 23 at 6:00 PM | seekingalpha.comTango Therapeutics, Inc. (TNGX) Discusses Positive Clinical Data and Development Plans for Vopimetostat in MTAP-deleted Cancers - SlideshowOctober 23 at 2:38 PM | seekingalpha.comTango Therapeutics stock falls after $210 million share offeringOctober 23 at 12:34 PM | investing.comTango Therapeutics Sub, Inc: Tango Therapeutics Announces $225 Million FinancingOctober 23 at 12:34 PM | finanznachrichten.deTango Therapeutics prices 21M shares at $8.66 in underwritten offeringOctober 23 at 12:34 PM | msn.comTango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer TherapyOctober 23 at 12:34 PM | msn.comTango Therapeutics Stock Falls After $210 Million Equity OfferingOctober 23 at 12:34 PM | tokenist.comTTango Therapeutics stock rises after strong pancreatic cancer trial dataOctober 23 at 12:34 PM | za.investing.comTango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund AdvancementOctober 23 at 11:17 AM | benzinga.comAssessing Tango Therapeutics (TNGX) Valuation After 170% Share Price Rally and Recent PullbackOctober 23 at 7:33 AM | finance.yahoo.comTango Therapeutics Announces $225 Million FinancingOctober 23 at 7:33 AM | markets.businessinsider.comTango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted CancersOctober 23 at 7:33 AM | markets.businessinsider.comTango Therapeutics Announces $225 Million FinancingOctober 23 at 7:20 AM | globenewswire.comTango Therapeutics granted orphan designation for treatment of malignant gliomaOctober 16, 2025 | msn.comTango Therapeutics (NASDAQ:TNGX) Reaches New 1-Year High - Here's WhyOctober 14, 2025 | marketbeat.comTango Therapeutics (NASDAQ:TNGX) Stock Price Up 13.9% - Should You Buy?October 13, 2025 | marketbeat.comTango Therapeutics' (TNGX) Sell (E+) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comTango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Moderate Buy" by BrokeragesOctober 7, 2025 | marketbeat.comTango Therapeutics to Present First Clinical Data from TNG260 at Society for Immunotherapy of Cancer (SITC) Annual Meeting 2025October 6, 2025 | globenewswire.comInsider Selling: Tango Therapeutics (NASDAQ:TNGX) Major Shareholder Sells 500,000 Shares of StockSeptember 30, 2025 | insidertrades.comTango Therapeutics (NASDAQ:TNGX) Major Shareholder Rock Ventures Iv L.P. Third Sells 500,000 SharesSeptember 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLFCR, TNGX, PROK, and PHAT Company DescriptionsLifecore Biomedical NASDAQ:LFCR$6.81 +0.07 (+1.04%) Closing price 04:00 PM EasternExtended Trading$6.80 0.00 (-0.07%) As of 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Phathom Pharmaceuticals NASDAQ:PHAT$13.61 +0.15 (+1.11%) Closing price 04:00 PM EasternExtended Trading$13.61 0.00 (0.00%) As of 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.ProKidney NASDAQ:PROK$3.19 +0.03 (+0.95%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.00 (+0.16%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.Tango Therapeutics NASDAQ:TNGX$7.53 -1.13 (-13.05%) Closing price 04:00 PM EasternExtended Trading$7.62 +0.09 (+1.13%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
